Related Experiment Video
Updated: Apr 1, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot
Aleksandra Sobolewska1, Marcin Włodarczyk2, Krystyna Stec-Michalska1
1Department of Gastroenterology, Medical University of Lodz, Haller Sq. 1, 90-647, Lodz, Poland.
Background:
The loss of response to infliximab in Crohn's disease (CD) patients is currently a major clinical problem. Recently, mean platelet volume (MPV) has been proposed as a new biomarker of CD activity. Here, we hypothesized that MPV may be used as cheap and efficient biomarker of subclinical inflammation during 52-week therapy in CD patients responding to infliximab induction treatment.
Aims:
The aim of study was to establish whether MPV at baseline and pre-infusion at week 14 are good predictors of sustained response after week 14 in CD patients undergoing 52-week infliximab therapy.
Methods:
A retrospective study of 30 adult CD patients who underwent a 52-week course of treatment with infliximab and achieved response at week 14 to induction treatment was performed. The association between MPV, baseline disease parameters and maintained clinical response or remission during infliximab therapy was assessed.
Results:
Higher MPV at week 14 was observed in CD patients with sustained response to infliximab after week 14 than in patients with loss of response (p = 0.0019). In patients with loss of response to maintenance infliximab treatment, lower ΔMPV between baseline and week 14 was calculated (p = 0.0003). MPV > 10.3 fl at week 14 predicts sustained response with 67 % sensitivity and 80 % specificity. ΔMPV between baseline and week 14 >0.4 fl predicts sustained response with 87 % sensitivity and 93 % specificity.
Conclusion:
MPV at week 14 and ΔMPV between baseline and week 14 are good predictors of sustained response to infliximab maintenance treatment in CD patients.
Insights
Mean platelet volume (MPV) can predict sustained response to infliximab therapy in Crohn's disease (CD) patients. Higher MPV at week 14 and changes in MPV indicate continued treatment effectiveness.
Area of Science:
- Gastroenterology
- Immunology
- Biomarker Discovery
Background:
- Loss of response to infliximab is a significant challenge in Crohn's disease (CD) management.
- Mean platelet volume (MPV) is emerging as a potential biomarker for CD activity.
- This study investigates MPV's utility in predicting sustained infliximab response in CD patients.
Purpose of the Study:
- To determine if baseline and week 14 MPV predict sustained response to infliximab therapy.
- To assess MPV as a cost-effective biomarker for subclinical inflammation during infliximab treatment.
Main Methods:
- Retrospective analysis of 30 adult CD patients receiving 52-week infliximab treatment.
- Patients achieved initial response at week 14.
- Association between MPV, disease parameters, and sustained clinical response/remission was evaluated.
Main Results:
- Higher MPV at week 14 correlated with sustained infliximab response (p = 0.0019).
- Lower MPV change (ΔMPV) from baseline to week 14 was linked to loss of response (p = 0.0003).
- MPV > 10.3 fl at week 14 predicted sustained response (67% sensitivity, 80% specificity); ΔMPV > 0.4 fl predicted sustained response (87% sensitivity, 93% specificity).
Conclusions:
- MPV measured at week 14 is a valuable predictor of sustained infliximab response in CD patients.
- The change in MPV (ΔMPV) from baseline to week 14 also effectively predicts sustained treatment response.
- MPV offers a simple and efficient method to monitor infliximab efficacy in Crohn's disease.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...